Valuation: APOE THERPAR

Market Cap 10.19B 8.99B 8.51B 7.71B 14.46B 977B 14.6B 102B 39.32B 499B 38.25B 37.42B 1,606B P/E 2027 *
-
P/E 2028 * -
Enterprise Value 9.29B 8.2B 7.76B 7.04B 13.19B 892B 13.32B 93.08B 35.87B 455B 34.89B 34.13B 1,465B EV / Sales 2027 *
-
EV / Sales 2028 * -
Free-Float
97.31%
Yield 2027 *
-
Yield 2028 * -
1 day-0.01%
Current month-0.01%
1 month+0.07%
3 months+1.86%
6 months+73.57%
Current year+78.95%
1 month 134.99
Extreme 134.99
135.09
Current year 60.35
Extreme 60.35
135.09
1 year 38.88
Extreme 38.88
135.09
3 years 14.19
Extreme 14.19
135.09
5 years 14.19
Extreme 14.19
135.09
10 years 14.19
Extreme 14.19
135.09
Manager TitleAgeSince
Director of Finance/CFO 60 01/01/2023
Chief Tech/Sci/R&D Officer - 01/05/2023
Chief Tech/Sci/R&D Officer 41 01/09/2022
Date Insider Type Main position Quantity % Market Cap. Importance
3/9/26
Fairmount Funds Management LLC
Issuer saleCompany -340,855 0.5480%
3/9/26 Issuer sale

Director

-48,780 0.0784%
3/9/26
Venrock Associates
Issuer saleCompany -2,115,853 3.4016%
Change 5-day change 1-year change 3-year change Capi.($)
-0.01%0.00%+239.12%+534.13% 10.19B
-0.39%+3.60%+10.39%+38.41% 48.85B
-0.73%-0.41%+48.84%+36.72% 44.28B
+1.36%+6.03%+343.85%+638.73% 43.83B
-0.47%-0.76%+9.75%+103.07% 41.53B
+0.34%+0.22%+5.18%+47.36% 30.13B
+1.00%-1.28%+24.23%+156.93% 17.36B
-0.79%-0.74%+22.37%+44.44% 14.99B
-2.94%+6.98%+5.10% - 14.9B
-0.86%-4.00% - - 14.98B
Average -0.14%+0.55%+78.76%+199.97% 28.1B
Weighted average by Cap. -0.08%+1.17%+81.07%+183.29%

Financials

2027 *2028 *
Net sales - -
Net income -372M -328M -311M -282M -528M -35.7B -533M -3.73B -1.44B -18.23B -1.4B -1.37B -58.67B -497M -439M -415M -376M -705M -47.68B -712M -4.98B -1.92B -24.35B -1.87B -1.83B -78.35B
Net Debt - -
Logo APOE THERPAR
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Ra. APG279 is for the dual inhibition of OX40L and IL-13.
Employees
261
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. APGE Stock